According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
A number of other research analysts also recently issued reports on OSUR. Canaccord Genuity restated a hold rating and issued a $8.00 price target on shares of OraSure Technologies in a research report on Monday, November 11th. ValuEngine upgraded shares of OraSure Technologies from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Finally, BidaskClub raised shares of OraSure Technologies from a sell rating to a hold rating in a research note on Saturday.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.18. OraSure Technologies had a return on equity of 5.93% and a net margin of 15.80%. The company had revenue of $35.99 million for the quarter, compared to analyst estimates of $38.62 million. During the same period in the previous year, the firm earned $0.13 earnings per share. The firm’s quarterly revenue was down 21.6% on a year-over-year basis. Sell-side analysts forecast that OraSure Technologies will post 0.14 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. Capital Fund Management S.A. acquired a new stake in OraSure Technologies during the second quarter worth approximately $160,000. Marshall Wace North America L.P. bought a new position in shares of OraSure Technologies during the 2nd quarter worth approximately $147,000. Pacer Advisors Inc. acquired a new stake in shares of OraSure Technologies during the 2nd quarter worth approximately $104,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $2,003,000. Finally, Russell Investments Group Ltd. increased its stake in shares of OraSure Technologies by 55.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 201,347 shares of the medical instruments supplier’s stock valued at $1,504,000 after acquiring an additional 71,678 shares in the last quarter. 95.66% of the stock is currently owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Further Reading: Street Name
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.